Literature DB >> 15275717

Efficacy of I131 ablation therapy using different doses as determined by postoperative thyroid scan uptake in patients with differentiated thyroid cancer.

Jamal Zidan1, Elioz Hefer, Galina Iosilevski, Karen Drumea, Moshe E Stein, Abraham Kuten, Ora Israel.   

Abstract

PURPOSE: The optimal dose of I(131) for ablation of functioning residual thyroid tissue after surgery is controversial. The current study was conducted to determine the optimal dose of I(131) for remnant postoperative ablation. A review of the literature is included. METHODS AND MATERIALS: A total of 238 patients with papillary and follicular carcinoma were treated with I(131) for ablation of a postoperative thyroid remnant. The I(131) dose was based on the 24-h percentage of neck uptake in the postoperative thyroid scans. Patients with < 5% uptake received a median of 85 mCi; 6-10% uptake, a median of 80 mCi; 11-15% uptake, a median of 60 mCi; 16-20% uptake, a median of 50 mCi; and > or =21% uptake, a median of 30 mCi. The ablation results were compared with the prognostic factors.
RESULTS: Complete ablation was observed in 40 (92%) of 43 patients receiving 85 mCi, in 31 (94%) of 33 who received 80 mCi, in 39 (95%) of 41 who received 60 mCi, in 51 (93%) of 55 who received 50 mCi, in 37 (94%) of 39 who received 30 mCi, and in 18 (96%) of 19 who received 30 mCi. The overall successful ablation rate was 94% (95% confidence interval, 89-100%).
CONCLUSION: Our findings suggest that patients with differentiated thyroid cancer can be treated with doses of I(131) according to the percentage of neck uptake of postoperative total body scan, with high complete ablation rates, without exposing patients to higher dose levels of I(131).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15275717     DOI: 10.1016/j.ijrobp.2004.01.036

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Ablation of the thyroid remnant and I-131 dose in differentiated thyroid cancer: a meta-analysis revisited.

Authors:  Suhail A R Doi; Nicholas J Woodhouse; Lukman Thalib; Adedayo Onitilo
Journal:  Clin Med Res       Date:  2007-06

Review 2.  Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Authors:  Chao Ma; Jiawei Xie; Wanxia Liu; Guoming Wang; Shuyao Zuo; Xufu Wang; Fengyu Wu
Journal:  Cochrane Database Syst Rev       Date:  2010-11-10

3.  Cisplatin based chemotherapy in patients with advanced differentiated thyroid carcinoma refractory to I131 treatment.

Authors:  Osama Hussein; Drumea Karen; Jamal Zidan
Journal:  Indian J Med Paediatr Oncol       Date:  2013-10

4.  Tumor necrosis factor-related apoptosis-inducing ligand additive with Iodine-131 of inhibits non-small cell lung cancer cells through promoting apoptosis.

Authors:  Ning Yang; Shuzhan Yao; Dong Liu
Journal:  Oncol Lett       Date:  2018-05-04       Impact factor: 2.967

5.  The Effects of the Factors Related to the Patient and the Disease on the Performance of Ablation Therapy in Patients with Differentiated Thyroid Cancer who have Received I-131 Ablation Therapy.

Authors:  Tarık Sengöz; Erdem Sürücü; Yusuf Demir; Erkan Derebek
Journal:  Mol Imaging Radionucl Ther       Date:  2012-12-20

6.  Metastatic colorectal cancer to a primary thyroid cancer.

Authors:  Martin H Cherk; Maggie Moore; Jonathan Serpell; Sarah Swain; Duncan J Topliss
Journal:  World J Surg Oncol       Date:  2008-11-11       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.